Global Monoclonal Antibodies (MAbS) Market Report 2024

Monoclonal Antibodies MAbS Global Market Report 2023 – By Source (Murine, Chimeric, Humanized, Human), By Application (Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular And Cerebrovascular, Other Applications), By End Users (Hospitals, Private Clinics, Research Institute) – Market Size, Trends, And Global Forecast 2023-2032

Starting Price : $5000.00 | Pages : 250 | Published : January 2023 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Monoclonal Antibodies (MAbS) Market

Proud Members Of

checkslacipN checkaoirsN checkscipN

Monoclonal antibodies (MABS) refer to laboratory-produced proteins intended to boost your immune system. Treatments for monoclonal antibodies are often administered as IV solutions, frequently in an infusion center. Antibodies are a component of your immune system.To kill them, they seek out the antigens (foreign substances) and adhere to them.

The main types of sources of monoclonal antibodies (MABS) are murine, chimeric, humanized, and human. A murine antibody has two types of chains, one of which is from a mouse and the other from a human. The pre-stem -o- in the INN of a murine antibody is used to identify it.It is used in anti-cancer, immunological, anti-infective monoclonal antibodies (MAbs), neuropharmacological, cardiovascular, cerebrovascular, and other applications and implemented in various sectors such as hospitals, private clinics, and research institutes.

The global monoclonal antibodies (MABs) market is segmented -

1) By Source: Murine, Chimeric, Humanized, Human

2) By Application: Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular And Cerebrovascular, Other Applications

3) By End Users: Hospitals, Private Clinics, Research Institute

The global monoclonal antibodies (mabs) market grew from $188.18 billion in 2022 to $209.98 billion in 2023 at a compound annual growth rate (CAGR) of 11.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The monoclonal antibodies (mabs) market is expected to grow from $330.35 billion in 2027 at a CAGR of 12.0%.

The increasing prevalence of cost-efficient biosimilar monoclonal antibodies is driving the monoclonal antibody market's growth. The biosimilars' aim is to curb the increasing cost of healthcare and handle economic pressure from the patient pod and governments to reduce the cost of medication and increase access to treatment. Biosimilars are pharmaceuticals that are developed to have similar properties to a biological drug that has already been approved. A biosimilar monoclonal antibody costs 20%–25% less than the original biologic drug. The number of clinical trials for a biosimilar is comparatively smaller than that of the original biologic drug, and this proves to be the reason for the low cost of a biosimilar drug. In India, a new biosimilar policy called the ‘Guidelines on Similar Biologics’ prepared by the Central Drugs Standard Control Organization (CSDCO) is expected to give a major boost to the Indian biosimilar drugs industry.

Major players in the monoclonal antibodies (MABS) market are Johnson & Johnson, Merck, AbbVie, Amgen, GlaxoSmithKline PLC., Norvatis AG, Pfizer Inc., Thermo Fisher Scientific, Eli Lilly and Company, and Bristol-Myers Squibb.

Alternative treatment methods and natural remedies are increasingly popular globally, and this is expected to hurt the revenues of the monoclonal antibody drugs market. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, and sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, the revenue from US retail sales of homeopathic and herbal remedies was around $7.5 billion. These less expensive alternatives increase the competitiveness of the biologics market, putting downward pressure on prices and limiting the demand for monoclonal antibody drugs.

The monoclonal antibody market has been witnessing multiple strategic initiatives in recent years. Top companies in the market are strategically acquiring start-ups and mid-sized companies to broaden their products and services. Strategic collaborations, acquisitions, and partnership agreements help vendors expand their existing product portfolio and geographical reach. For instance, in March 2022, Sanofi S.A., a France based pharmaceutical and healthcare company specialising in the discovery, development, manufacturing, and commercialization of drugs, announced a strategic collaboration with Seagen Inc., a US-based pharmaceutical company specialising in the development and commercialization of novel, powerful monoclonal antibody-based cancer treatments. Under this agreement, the partnership will use Seagen's and Sanofi's exclusive monoclonal antibody (mAb) and antibody-drug conjugate (ADC) technologies to design, develop, and market ADCs for up to three cancer targets. Furthermore, Boehringer Ingelheim, a Germany-based research-driven pharmaceutical company, announced a collaboration with MabGenesis, Inc., a Japan-based biopharmaceutical company pioneering in the development of therapeutic monoclonal antibody drugs for the treatment of human diseases. Through this collaboration, Boehringer Ingelheim and MabGenesis discover and develop novel therapeutic monoclonal antibodies for the treatment of various diseases and strategic research and development strategies. Companies in the industry are increasingly realigning their portfolios and pursuing profitable inorganic growth opportunities. Additionally, M&A interest is also being fueled by stronger corporate balance sheets, liquid debt markets, and continued favourable interest rates globally.

The Food and Drug Administration (FDA) is a federal agency of the United States Department of Health and Human Services, in the USA, regulating the monoclonal antibody and pharmaceutical drug markets. Increasing product launches and regulatory support for the treatment of rare diseases by the USFDA are expected to support the monoclonal antibody therapeutics market's growth. For instance, the U.S. The Food and Drug Administration (FDA) granted accelerated approval to avelumab (BAVENCIO, EMD Serono, Inc.), a human monoclonal antibody, for the treatment of a rare disease, metastatic Merkel cell carcinoma (MCC). Similarly, the U.S. FDA granted accelerated approval to the immunotherapy product TECENTRIQ (atezolizumab), a humanized, engineered monoclonal antibody, for the treatment of people with locally-advanced or metastatic urothelial carcinoma (MUC).

North America was the largest region in the monoclonal antibodies (MAbS) market in 2022.

The regions covered in the global monoclonal antibodies (MABS) market analysis are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the monoclonal antibodies (MABS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA.

The monoclonal antibodies (MABS) market consists of sales of rituximab, cetuximab, and trastuzumab. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products.

The monoclonal antibodies (MABS) market research report is one of a series of new reports from The Business Research Company that provides monoclonal antibodies (MABS) market statistics, such as industry global market size, regional shares, competitors with a monoclonal antibodies (MABS) market share, detailed monoclonal antibodies (MABS) market segments, market trends and opportunities, and any additional data you may require to thrive in the monoclonal antibodies (MABS) industry.This monoclonal antibody (MABS) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

    Table Of Contents

    1. Executive Summary

    2. Monoclonal Antibodies (MAbS) Market Characteristics

    3. Monoclonal Antibodies (MAbS) Market Trends And Strategies

    4. Monoclonal Antibodies (MAbS) Market – Macro Economic Scenario

    4.1 COVID-19 Impact On Monoclonal Antibodies (MAbS) Market

    4.2 Ukraine-Russia War Impact On Monoclonal Antibodies (MAbS) Market

    4.3 Impact Of High Inflation On Monoclonal Antibodies (MAbS) Market

    5. Monoclonal Antibodies (MAbS) Market Size And Growth

    5.1. Global Monoclonal Antibodies (MAbS) Historic Market, 2017-2022, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Monoclonal Antibodies (MAbS) Forecast Market, 2022-2027F, 2032F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Monoclonal Antibodies (MAbS) Market Segmentation

    6.1. Global Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Murine

    Chimeric

    Humanized

    Human

    6.2. Global Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Anti-Cancer

    Immunological

    Anti-Infective Monoclonal Antibodies (Mabs)

    Neuropharmacological

    Cardiovascular And Cerebrovascular

    Others

    6.3. Global Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Hospitals

    Private Clinics

    Research Institute

    7. Monoclonal Antibodies (MAbS) Market Regional And Country Analysis

    7.1. Global Monoclonal Antibodies (MAbS) Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    7.2. Global Monoclonal Antibodies (MAbS) Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8. Asia-Pacific Monoclonal Antibodies (MAbS) Market

    8.1. Asia-Pacific Monoclonal Antibodies (MAbS) Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8.3. Asia-Pacific Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8.4. Asia-Pacific Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    9. China Monoclonal Antibodies (MAbS) Market

    9.1. China Monoclonal Antibodies (MAbS) Market Overview

    9.2. China Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    9.3. China Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    9.4. China Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    10. India Monoclonal Antibodies (MAbS) Market

    10.1. India Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    10.2. India Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    10.3. India Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11. Japan Monoclonal Antibodies (MAbS) Market

    11.1. Japan Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11.2. Japan Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11.3. Japan Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12. Australia Monoclonal Antibodies (MAbS) Market

    12.1. Australia Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12.2. Australia Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12.3. Australia Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13. Indonesia Monoclonal Antibodies (MAbS) Market

    13.1. Indonesia Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13.2. Indonesia Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13.3. Indonesia Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14. South Korea Monoclonal Antibodies (MAbS) Market

    14.1. South Korea Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14.2. South Korea Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14.3. South Korea Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15. Western Europe Monoclonal Antibodies (MAbS) Market

    15.1. Western Europe Monoclonal Antibodies (MAbS) Market Overview

    15.2. Western Europe Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15.3. Western Europe Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15.4. Western Europe Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16. UK Monoclonal Antibodies (MAbS) Market

    16.1. UK Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16.2. UK Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16.3. UK Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17. Germany Monoclonal Antibodies (MAbS) Market

    17.1. Germany Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17.2. Germany Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17.3. Germany Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18. France Monoclonal Antibodies (MAbS) Market

    18.5. France Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18.6. France Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18.7. France Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19. Eastern Europe Monoclonal Antibodies (MAbS) Market

    19.1. Eastern Europe Monoclonal Antibodies (MAbS) Market Overview

    19.2. Eastern Europe Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19.3. Eastern Europe Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19.4. Eastern Europe Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20. Russia Monoclonal Antibodies (MAbS) Market

    20.1. Russia Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20.2. Russia Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20.3. Russia Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21. North America Monoclonal Antibodies (MAbS) Market

    21.1. North America Monoclonal Antibodies (MAbS) Market Overview

    21.2. North America Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21.3. North America Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21.4. North America Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22. USA Monoclonal Antibodies (MAbS) Market

    22.1. USA Monoclonal Antibodies (MAbS) Market Overview

    22.2. USA Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22.3. USA Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22.4. USA Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23. South America Monoclonal Antibodies (MAbS) Market

    23.1. South America Monoclonal Antibodies (MAbS) Market Overview

    23.2. South America Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23.3. South America Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23.4. South America Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24. Brazil Monoclonal Antibodies (MAbS) Market

    24.1. Brazil Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24.2. Brazil Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24.3. Brazil Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25. Middle East Monoclonal Antibodies (MAbS) Market

    25.1. Middle East Monoclonal Antibodies (MAbS) Market Overview

    25.2. Middle East Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25.3. Middle East Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25.4. Middle East Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26. Africa Monoclonal Antibodies (MAbS) Market

    26.1. Africa Monoclonal Antibodies (MAbS) Market Overview

    26.2. Africa Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26.3. Africa Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26.4. Africa Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    27. Monoclonal Antibodies (MAbS) Market Competitive Landscape And Company Profiles

    27.1. Monoclonal Antibodies (MAbS) Market Competitive Landscape

    27.2. Monoclonal Antibodies (MAbS) Market Company Profiles

    27.2.1. Johnson & Johnson

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Merck

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. AbbVie

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Amgen

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Glaxosmithkline plc

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Monoclonal Antibodies (MAbS) Pipeline Analysis

    29. Key Mergers And Acquisitions In The Monoclonal Antibodies (MAbS) Market

    30. Monoclonal Antibodies (MAbS) Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Historic And Forecast Inflation Rates

    31.4. Research Inquiries

    31.5. The Business Research Company

    31.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Table 3: Global Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 4: Global Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 5: Global Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 6: Global Monoclonal Antibodies (MAbS) Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 7: Global Monoclonal Antibodies (MAbS) Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 8: Asia-Pacific, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 9: Asia-Pacific, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 10: Asia-Pacific, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 11: China, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 12: China, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 13: China, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 14: India, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 15: India, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 16: India, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 17: Japan, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 18: Japan, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 19: Japan, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 20: Australia, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 21: Australia, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 22: Australia, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 23: Indonesia, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 24: Indonesia, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 25: Indonesia, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 26: South Korea, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 27: South Korea, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 28: South Korea, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 29: Western Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 30: Western Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 31: Western Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 32: UK, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 33: UK, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 34: UK, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 35: Germany, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 36: Germany, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 37: Germany, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 38: France, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 39: France, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 40: France, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 41: Eastern Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 42: Eastern Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 43: Eastern Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 44: Russia, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 45: Russia, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 46: Russia, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 47: North America, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 48: North America, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 49: North America, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 50: USA, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 51: USA, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 52: USA, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 53: South America, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 54: South America, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 55: South America, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 56: Brazil, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 57: Brazil, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 58: Brazil, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 59: Middle East, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 60: Middle East, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 61: Middle East, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 62: Africa, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 63: Africa, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 64: Africa, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 65: Johnson & Johnson Financial Performance
  • Table 66: Merck Financial Performance
  • Table 67: AbbVie Financial Performance
  • Table 68: Amgen Financial Performance
  • Table 69: Glaxosmithkline plc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Figure 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Figure 3: Global Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 4: Global Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 5: Global Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 6: Global Monoclonal Antibodies (MAbS) Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 7: Global Monoclonal Antibodies (MAbS) Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 8: Asia-Pacific, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 9: Asia-Pacific, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 10: Asia-Pacific, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 11: China, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 12: China, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 13: China, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 14: India, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 15: India, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 16: India, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 17: Japan, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 18: Japan, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 19: Japan, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 20: Australia, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 21: Australia, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 22: Australia, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 23: Indonesia, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 24: Indonesia, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 25: Indonesia, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 26: South Korea, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 27: South Korea, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 28: South Korea, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 29: Western Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 30: Western Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 31: Western Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 32: UK, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 33: UK, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 34: UK, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 35: Germany, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 36: Germany, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 37: Germany, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 38: France, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 39: France, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 40: France, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 41: Eastern Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 42: Eastern Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 43: Eastern Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 44: Russia, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 45: Russia, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 46: Russia, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 47: North America, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 48: North America, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 49: North America, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 50: USA, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 51: USA, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 52: USA, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 53: South America, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 54: South America, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 55: South America, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 56: Brazil, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 57: Brazil, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 58: Brazil, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 59: Middle East, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 60: Middle East, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 61: Middle East, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 62: Africa, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 63: Africa, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 64: Africa, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 65: Johnson & Johnson Financial Performance
  • Figure 66: Merck Financial Performance
  • Figure 67: AbbVie Financial Performance
  • Figure 68: Amgen Financial Performance
  • Figure 69: Glaxosmithkline plc Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report